![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 38, 35616-35624, September 20, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Departments of The absence or reduced activity of coagulation
factor IX (FIX) causes the severe bleeding disorder hemophilia B. FIX
contains an N-terminal Gla domain followed by two epidermal growth
factor-like (EGF) domains and a serine protease domain. In this study,
the epitope of monoclonal antibody AW, which is directed against the C-terminal part of the first EGF domain in human FIX, was defined, and
the antibody was used to study interactions between the EGF domain of
FIX and other coagulation proteins. Antibody AW completely blocks
activation of FIX by activated factor XI, but activation by activated
factor FVII-tissue factor is inhibited only slightly. The antibody also
causes a marginal reduction in the apparent kcat for factor X both in the presence and
absence of activated factor VIII. Based on these results, we produced a
preliminary model of the structure of the activated factor IX-activated
factor VIII-AW complex on the surface of phospholipid. The model
suggests that in the Xase complex, EGF1 of activated factor IX is not
involved in direct binding to activated factor VIII. Studies of the
interaction of antibody AW with a mutated FIX molecule (R94D) also
suggest that the Glu78-Arg94 salt bridge is
not important for maintaining the structure of FIX.
The N-terminal Epidermal Growth Factor-like Domain of Coagulation
Factor IX
PROBING ITS FUNCTIONS IN THE ACTIVATION OF FACTOR IX AND FACTOR
X WITH A MONOCLONAL ANTIBODY*
,
,
, and
**
Clinical Chemistry and
Pediatrics, Lund University, University Hospital,
Malmö, S-205 02 Malmö, Sweden and the § Institut
National de la Santé et de la Recherche Médicale,
INSERM U428, Université Paris V, 4 Ave de L'Observatoire,
Paris 75006, France
*
This work was supported by Malmö University Hospital,
the Swedish Research Council (Medicine), and the Swedish Governmental Funding for Clinical Research.The costs of publication of this article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
This article has been cited by other articles:
![]() |
X. Yang, Y.-J. Chang, S.-W. Lin, and P. N. Walsh Identification of Residues Asn89, Ile90, and Val107 of the Factor IXa Second Epidermal Growth Factor Domain That Are Essential for the Assembly of the Factor X-activating Complex on Activated Platelets J. Biol. Chem., November 5, 2004; 279(45): 46400 - 46405. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Blostein, B. C. Furie, I. Rajotte, and B. Furie The Gla Domain of Factor IXa Binds to Factor VIIIa in the Tenase Complex J. Biol. Chem., August 15, 2003; 278(33): 31297 - 31302. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Shikamoto, T. Morita, Z. Fujimoto, and H. Mizuno Crystal Structure of Mg2+- and Ca2+-bound Gla Domain of Factor IX Complexed with Binding Protein J. Biol. Chem., June 20, 2003; 278(26): 24090 - 24094. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Thiec, G. Cherel, and O. D. Christophe Role of the Gla and First Epidermal Growth Factor-like Domains of Factor X in the Prothrombinase and Tissue Factor-Factor VIIa Complexes J. Biol. Chem., March 14, 2003; 278(12): 10393 - 10399. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |